Literature DB >> 10528187

4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.

J T Tan1, J K Whitmire, R Ahmed, T C Pearson, C P Larsen.   

Abstract

4-1BB (CD137) is a costimulatory molecule expressed on activated T cells and interacts with 4-1BB ligand (4-1BBL) on APCs. To investigate the role of 4-1BB costimulation for the development of primary immune responses, 4-1BBL-deficient (4-1BBL-/-) mice were infected with lymphocytic choriomeningitis virus (LCMV). 4-1BBL-/- mice were able to generate CTL and eliminate acute LCMV infection with normal kinetics, but CD8 T cell expansion was 2- to 3-fold lower than in wild-type (+/+) mice. In the same mice, virus-specific CD4 Th and B cell responses were minimally affected, indicating that 4-1BB costimulation preferentially affects CD8 T cell responses. This result contrasts with our earlier work with CD40L-deficient (CD40L-/-) mice, in which the CD8 T cell response was unaffected and the CD4 T cell response was markedly impaired. When both 4-1BBL- and B7-dependent signals were absent, CD8 T cell expansion was further reduced, resulting in lower CTL activity and impairing their ability to clear LCMV. Altogether, these results indicate that T cells have distinct costimulatory requirements: optimal CD8 responses require 4-1BBL-dependent interactions, whereas CD4 responses are minimally affected by 4-1BB costimulation, but require CD40-CD40L and B7-dependent interactions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528187

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

Review 1.  A novel helper role for CD4 T cells.

Authors:  J M den Haan; M J Bevan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

2.  High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection.

Authors:  J D Ahlers; I M Belyakov; E K Thomas; J A Berzofsky
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

3.  Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes.

Authors:  Hajir Dadgostar; Brian Zarnegar; Alexander Hoffmann; Xiao-Feng Qin; Uyen Truong; Govinda Rao; David Baltimore; Genhong Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

Review 4.  T-cell activation and transplantation tolerance.

Authors:  Bhavana Priyadharshini; Dale L Greiner; Michael A Brehm
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

5.  Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function.

Authors:  Amy D H Doody; Joseph T Kovalchin; Marianne A Mihalyo; Adam T Hagymasi; Charles G Drake; Adam J Adler
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

6.  CD137: costimulator turns suppressor?

Authors:  Aymen Al-Shamkhani
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

7.  Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro.

Authors:  Kailin Xu; Chaohong Li; Xiuying Pan; Bing Du
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 8.  The many sounds of T lymphocyte silence.

Authors:  Ignacio Melero; Ainhoa Arina; Lieping Chen
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

9.  Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice.

Authors:  Sujin Lee; Robert S Mittler; Martin L Moore
Journal:  J Immunol       Date:  2013-11-27       Impact factor: 5.422

10.  Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.

Authors:  Xiao-Song Zhong; Maiko Matsushita; Jason Plotkin; Isabelle Riviere; Michel Sadelain
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.